อ้างอิง ของ ไลโพโปรตีนหนาแน่นสูง

  1. ↑ "LDL and HDL: Bad and Good Cholesterol". Centers for Disease Control and Prevention. CDC. สืบค้นเมื่อ 2017-09-11.
  2. ↑ Betteridge; และคณะ (2008). "Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor". PNAS. 105 (35): 13045–13050. doi:10.1073/pnas.0806312105. PMC 2526098.CS1 maint: Explicit use of et al. (link)
  3. ↑ "LDL and HDL Cholesterol: What's Bad and What's Good?". American Heart Association. 2009-07-02. สืบค้นเมื่อ 2009-10-08.
  4. ↑ Toth, PP (February 2005). "Cardiology patient page. The "good cholesterol": high-density lipoprotein". Circulation. 111 (5): e89–e91. doi:10.1161/01.CIR.0000154555.07002.CA. PMID 15699268.CS1 maint: Uses authors parameter (link)
  5. ↑ Sirtori, Cesare R. (October 2006). "HDL and the progression of atherosclerosis: new insights". European Heart Journal Supplements.
  6. 1 2 "NIH stops clinical trial on combination cholesterol treatment". National Institute of Health. National Heart, Lung, and Blood Institute (NHLBI). สืบค้นเมื่อ 2011-06-02.
  7. ↑ Sorrentino, MJ (2011), "Non-HDL-Cholesterol", Hyperlipidemia in Primary Care, pp. 86–87, ISBN 978-1-60327-502-6
  8. ↑ Després, Jean-Pierre. "The Atherogenic Triad of New Metabolic Risk Factors: Importance of Waist and Fasting Triglycerides as Screening Tools". Visceral Adipose Tissue and Cardiometabolic Risk: Does It Really Matter? Part 2. สืบค้นเมื่อ 2009-10-08. [แหล่งข้อมูลที่ตีพิมพ์เอง?]
  9. ↑ Bibow, S; et. al. (2017), "Solution structure of discoidal high-density lipoprotein particles with a shortened apolipoprotein A-I", Nature Structural & Molecular Biology, 24 (6): 187–93, doi:10.1038/nsmb.3345CS1 maint: Uses authors parameter (link)
  10. ↑ Huang, CX; Zhang, YL (2013). "The target of regulating the ATP-binding cassette A1 protein (ABCA1) : promoting ABCA1-mediated cholesterol efflux in different cells". Current Pharmaceutical Biotechnology. 14 (6): 623–31. doi:10.2174/138920101131400228. PMID 24016265.CS1 maint: Uses authors parameter (link)
  11. ↑ Stephens, NA; Kieft, R; Macleod, A; Hajduk, SL (December 2012). "Trypanosome resistance to human innate immunity: targeting Achilles' heel". Trends in Parasitology. 28 (12): 539–45. doi:10.1016/j.pt.2012.09.002. PMC 4687903. PMID 23059119.CS1 maint: Uses authors parameter (link)
  12. ↑ Kwiterovich, PO (December 2000). "The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review". The American Journal of Cardiology. 86 (12A): 5L–10L. doi:10.1016/S0002-9149(00)01461-2. PMID 11374859.CS1 maint: Uses authors parameter (link)
  13. ↑ "HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men". 1991. PMID 2060089.
  14. ↑ Ruidavets, JB; Ducimetière, P; Arveiler, D; Amouyel, P; Bingham, A; Wagner, A; Cottel, D; Perret, B; Ferrières, J (January 2002). "Types of alcoholic beverages and blood lipids in a French population". Journal of Epidemiology and Community Health. 56 (1): 24–8. doi:10.1136/jech.56.1.24. PMC 1732002. PMID 11801616.CS1 maint: Uses authors parameter (link)
  15. ↑ "Partial thromboplastin time (PTT)". MedlinePlus Medical Encyclopedia. Archived from the original on 2018-11-27. สืบค้นเมื่อ 2009-01-01.
  16. ↑ Mard-Soltani, M; Dayer, MR; Shamshirgar-Zadeh, A; Ali-Bahar, H; Nasirbagheban, Z (April 2012). "The Buffering Role of HDL in Balancing the Effects of Hypercoagulable State in Type 2 Diabetes". J Applied sciences. 12 (8): 745–52. doi:10.3923/jas.2012.745.752.CS1 maint: Uses authors parameter (link)
  17. ↑ Rahilly-Tierney, CR; Spiro, A; Vokonas, P; Gaziano, JM (April 2011). "Relation between high-density lipoprotein cholesterol and survival to age 85 years in men (from the VA normative aging study)". The American Journal of Cardiology. 107 (8): 1173–7. doi:10.1016/j.amjcard.2010.12.015. PMID 21296318.CS1 maint: Uses authors parameter (link)
  18. ↑ Rubins, HB; Robins, SJ; Collins, D; Nelson, DB; Elam, MB; Schaefer, EJ; Faas, FH; Anderson, JW (2002). "Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT)". Archives of Internal Medicine. 162 (22): 2597–604. doi:10.1001/archinte.162.22.2597. PMID 12456232.CS1 maint: Uses authors parameter (link)
  19. ↑ Barter, P; Gotto, AM; LaRosa, JC; Maroni, J; Szarek, M; Grundy, SM; Kastelein, JJ; Bittner, V; Fruchart, JC (September 2007). "HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events". The New England Journal of Medicine. 357 (13): October 1301. doi:10.1056/NEJMoa064278. PMID 17898099.CS1 maint: Uses authors parameter (link)
  20. ↑ "National Reference System for Cholesterol - Cholesterol Reference Method Laboratory Network - HDL Cholesterol Certification Protocol for Manufacturers" (PDF). CDC. สืบค้นเมื่อ 2013-11-10.
  21. ↑ Warnick, GR; Nauck, M; Rifai, N (September 2001). "Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays". Clinical Chemistry. 47 (9): 1579–1596. PMID 11514391.CS1 maint: Uses authors parameter (link)
  22. ↑ Okazaki, M; Sasamoto, K; Muramatsu, T; Hosaki, S (October 1997). "Evaluation of precipitation and direct methods for HDL-cholesterol assay by HPLC". Clinical Chemistry. 43 (10): 1885–90. PMID 9342008.CS1 maint: Uses authors parameter (link)
  23. ↑ Hirano, T; Nohtomi, K; Koba, S; Muroi, A; Ito, Y (May 2008). "A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay". Journal of Lipid Research. 49 (5): 1130–6. doi:10.1194/jlr.D700027-JLR200. PMID 18223297.CS1 maint: Uses authors parameter (link)
  24. ↑ Superko, HR; Pendyala, L; Williams, PT; Momary, KM; 3rd, King SB; Garrett, BC (2012). "High-density lipoprotein subclasses and their relationship to cardiovascular disease". Journal of Clinical Lipidology. 6 (6): 496–523. doi:10.1016/j.jacl.2012.03.001. PMID 23312047.CS1 maint: Uses authors parameter (link)
  25. ↑ "Cholesterol Levels". American Heart Association. Archived from the original on 2010-02-08. สืบค้นเมื่อ 2009-11-14.
  26. ↑ "What Do My Cholesterol Levels Mean?" (PDF). American Heart Association. September 2007. Archived from the original (PDF) on 2008-12-03. สืบค้นเมื่อ 2009-11-14.
  27. ↑ "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary" (PDF). National Heart, Lung, and Blood Institute (NHLBI). National Institutes of Health. May 2001.
  28. ↑ ASHWOOD, ER; BURTIS, CA; BRUNS, DE (2008). Tietz fundamentals of clinical chemistry (6th ed.). St. Louis, MO: Saunders Elsevier. p. 415.CS1 maint: Uses authors parameter (link)
  29. ↑ Jeyarajah, EJ; Cromwell, WC; Otvos, JD (2006). "Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy". Clin. Lab. Med. 26 (4): 847–70. doi:10.1016/j.cll.2006.07.006. PMID 17110242.CS1 maint: Uses authors parameter (link)
  30. ↑ mesa-nhlbi.org
  31. ↑ Singh-Manoux, A; Gimeno, D; Kivimaki, M; Brunner, E; Marmot, MG (August 2008). "Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study". Arteriosclerosis, Thrombosis, and Vascular Biology. 28 (8): 1556–62. doi:10.1161/ATVBAHA.108.163998. PMC 2581752. PMID 18591462.CS1 maint: Uses authors parameter (link)
  32. ↑ Keene, D; Price, C; Shun-Shin, MJ; Francis, DP (2014-07-18). "Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients". BMJ. 349: g4379. doi:10.1136/bmj.g4379. PMC 4103514. PMID 25038074.CS1 maint: Uses authors parameter (link)
  33. ↑ Sacks, FM; Zheng, C; Cohn, JS (2011). "Complexities of plasma apolipoprotein C-III metabolism". Journal of Lipid Research. 52 (6): 1067–1070. doi:10.1194/jlr.E015701. PMC 3090227. PMID 21421846.CS1 maint: Uses authors parameter (link)
  34. ↑ Fogoros, Richard N. (2009-09-15). "Raising Your HDL Levels Increasing the GOOD cholesterol". About.com. สืบค้นเมื่อ 2009-10-08.
  35. ↑ "Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials". Ajcn.org. สืบค้นเมื่อ 2015-11-05.
  36. ↑ Ma, Y; Li, Y; Chiriboga, DE; Olendzki, BC; Hebert, JR; Li, W; Leung, K; Hafner, AR; Ockene, IS (April 2006). "Association between carbohydrate intake and serum lipids". Journal of the American College of Nutrition. 25 (2): 155–163. doi:10.1080/07315724.2006.10719527. PMC 1479303. PMID 16582033. Archived from the original on 2012-01-15. สืบค้นเมื่อ 2012-09-01.CS1 maint: Uses authors parameter (link)
  37. ↑ Siri-Tarino, PW; Sun, Q; Hu, FB; Krauss, RM (March 2010). "Saturated fat, carbohydrate, and cardiovascular disease". The American Journal of Clinical Nutrition. 91 (3): 502–9. doi:10.3945/ajcn.2008.26285. PMC 2824150. PMID 20089734.CS1 maint: Uses authors parameter (link)
  38. ↑ Krauss, RM; Blanche, PJ; Rawlings, RS; Fernstrom, HS; Williams, PT (May 2006). "Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia". The American Journal of Clinical Nutrition. 83 (5): 1025–1031. PMID 16685042.CS1 maint: Uses authors parameter (link)
  39. ↑ Spate-Douglas, T; Keyser, RE (June 1999). "Exercise intensity: its effect on the high-density lipoprotein profile". Archives of Physical Medicine and Rehabilitation. 80 (6): 691–5. doi:10.1016/S0003-9993(99)90174-0. PMID 10378497.CS1 maint: Uses authors parameter (link)
  40. 1 2 Hausenloy, DJ; Yellon, DM (June 2008). "Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels". Heart. 94 (6): 706–14. doi:10.1136/hrt.2007.125401. PMID 18480348.CS1 maint: Uses authors parameter (link)
  41. ↑ Rosanoff, A; Seelig, MS (October 2004). "Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals". Journal of the American College of Nutrition. 23 (5): 501S–505S. doi:10.1080/07315724.2004.10719389. PMID 15466951. Archived from the original on 2010-08-31. สืบค้นเมื่อ 2010-12-13. HMG CoA Reductase is an important enzyme in lipid and cholesterol metabolism, but it is not the only one. The statins act by inhibiting, temporarily, the enzyme, in a dose response relationship whereas the magnesium ion (Mg2+) is an important part of a complex control and regulation of this important pathway. Both lower LDL-C, some statins can raise HDL-C and lower triglycerides, but Mg supplements do both quite reliably.CS1 maint: Uses authors parameter (link)
  42. ↑ Hermansen, K; Dinesen, B; Hoie, LH; Morgenstern, E; Gruenwald, J (2003). "Effects of soy and other natural products on LDL:HDL ratio and other lipid parameters: a literature review". Advances in Therapy. 20 (1): 50–78. doi:10.1007/bf02850119. PMID 12772818.CS1 maint: Uses authors parameter (link)
  43. ↑ "The Power of Fish". The Cleveland Clinic Heart and Vascular Institute. สืบค้นเมื่อ 2009-10-08.
  44. ↑ "Vitamins and Supplements Lifestyle Guide - Flaxseed". WebMD. สืบค้นเมื่อ 2013-08-12.
  45. ↑ Aksoy, N; Aksoy, M; Bagci, C; Gergerlioglu, HS; Celik, H; Herken, E; Yaman, A; Tarakcioglu, M; Soydinc, S; Sari, I; Davutoglu, V (2007). "Pistachio intake increases high density lipoprotein levels and inhibits low-density lipoprotein oxidation in rats". The Tohoku Journal of Experimental Medicine. 212 (1): 43–48. doi:10.1620/tjem.212.43. PMID 17464102.CS1 maint: Uses authors parameter (link) [ลิงก์เสีย]
  46. ↑ Mensink, RP; Zock, PL; Kester, AD; Katan, MB (May 2003). "Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials". The American Journal of Clinical Nutrition. 77 (5): 1146–55. PMID 12716665.CS1 maint: Uses authors parameter (link)
  47. ↑ "Trans fat: Avoid this cholesterol double whammy". Mayo Foundation for Medical Education and Research (MFMER). สืบค้นเมื่อ 2010-06-25.
  48. ↑ Thijssen, MA; Mensink, RP (2005). von Eckardstein, Arnold, eds. Fatty Acids and Atherosclerotic Risk. Atherosclerosis: Diet and Drugs. Springer. pp. 171–172.CS1 maint: Uses authors parameter (link) CS1 maint: Uses editors parameter (link)
  49. 1 2 Soudijn, W; van Wijngaarden, I; Ijzerman, AP (May 2007). "Nicotinic acid receptor subtypes and their ligands". Medicinal Research Reviews. 27 (3): 417–33. doi:10.1002/med.20102. PMID 17238156.CS1 maint: Uses authors parameter (link)
  50. ↑ Baer, DJ; Judd, JT; Clevidence, BA; Muesing, RA; Campbell, WS; Brown, ED; Taylor, PR (March 2002). "Moderate alcohol consumption lowers risk factors for cardiovascular disease in postmenopausal women fed a controlled diet". The American Journal of Clinical Nutrition. 75 (3): 593–599. doi:10.1093/ajcn/75.3.593. PMID 11864868.CS1 maint: Uses authors parameter (link)
  51. ↑ van der Gaag, MS; van Tol, A; Vermunt, SH; Scheek, LM; Schaafsma, G; Hendriks, HF (December 2001). "Alcohol consumption stimulates early steps in reverse cholesterol transport". Journal of Lipid Research. 42 (12): 2077–2083. PMID 11734581.CS1 maint: Uses authors parameter (link)
  52. ↑ Hendriks, HF; Veenstra, J; van Tol, A; Groener, JE; Schaafsma, G (1998). "Moderate doses of alcoholic beverages with dinner and postprandial high density lipoprotein composition". Alcohol and Alcoholism. 33 (4): 403–410. doi:10.1093/oxfordjournals.alcalc.a008410. PMID 9719399.CS1 maint: Uses authors parameter (link)
  53. ↑ Clevidence, BA; Reichman, ME; Judd, JT; Muesing, RA; Schatzkin, A; Schaefer, EJ; Li, Z; Jenner, J; Brown, CC; Sunkin, M (February 1995). "Effects of alcohol consumption on lipoproteins of premenopausal women. A controlled diet study". Arteriosclerosis, Thrombosis, and Vascular Biology. 15 (2): 179–184. doi:10.1161/01.ATV.15.2.179. PMID 7749823.CS1 maint: Uses authors parameter (link)
  54. ↑ Cuvelier, I; Steinmetz, J; Mikstacki, T; Siest, G (May 1985). "Variations in total phospholipids and high-density lipoprotein phospholipids in plasma from a general population: reference intervals and influence of xenobiotics". Clinical Chemistry. 31 (5): 763–766. PMID 3987006.CS1 maint: Uses authors parameter (link)
  55. ↑ Brenn, T (September 1986). "The Tromsø heart study: alcoholic beverages and coronary risk factors". Journal of Epidemiology and Community Health. 40 (3): 249–256. doi:10.1136/jech.40.3.249. PMC 1052533. PMID 3772283.CS1 maint: Uses authors parameter (link)
  56. 1 2 Penner, EA; Buettner, H; Mittleman, MA (July 2013). "The impact of marijuana use on glucose, insulin, and insulin resistance among US adults". The American Journal of Medicine. 126 (7): 583–9. doi:10.1016/j.amjmed.2013.03.002. PMID 23684393.CS1 maint: Uses authors parameter (link)
  57. ↑ Benatar, JR; Stewart, RA (2007). "Is it time to stop treating dyslipidaemia with fibrates?". The New Zealand Medical Journal. 120 (1261): U2706. PMID 17853928. Archived from the original on 2009-07-06. สืบค้นเมื่อ 2009-04-29.CS1 maint: Uses authors parameter (link)
  58. ↑ Meyers, CD; Kamanna, VS; Kashyap, ML (December 2004). "Niacin therapy in atherosclerosis". Current Opinion in Lipidology. 15 (6): 659–65. doi:10.1097/00041433-200412000-00006. PMID 15529025.CS1 maint: Uses authors parameter (link)
  59. ↑ Rader, Daniel J. (2004). "Raising HDL in Clinical Practice". Raising HDL in Clinical Practice: Clinical Strategies to Elevate HDL. สืบค้นเมื่อ 2009-10-08.
  60. 1 2 Brewer, H. Bryan (2005-12-27). "Raising HDL-Cholesterol and Reducing Cardiovascular Risk: An Expert Interview With H. Bryan Brewer, Jr, MD". สืบค้นเมื่อ 2009-10-08.
  61. ↑ Chapman, MJ; Assmann, G; Fruchart, JC; Shepherd, J; Sirtori, C; HDL-C)), ((European Consensus Panel on (August 2004). "Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C". Current Medical Research and Opinion. 20 (8): 1253–68. doi:10.1185/030079904125004402. PMID 15324528.CS1 maint: Uses authors parameter (link)
  62. ↑ Drexel, H. (2006). "Reducing risk by raising HDL-cholesterol: the evidence". European Heart Journal Supplements. 8: F23. doi:10.1093/eurheartj/sul037.
  63. ↑ Meyers, CD; Carr, MC; Park, S; Brunzell, JD (December 2003). "Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia". Annals of Internal Medicine. 139 (12): 996–1002. doi:10.7326/0003-4819-139-12-200312160-00009. PMID 14678919.CS1 maint: Uses authors parameter (link)
  64. ↑ "Study: Boosting Good Cholesterol With Niacin Did Not Cut Heart Risks : Shots - Health News". NPR. 2011-05-26. สืบค้นเมื่อ 2015-11-05.
  65. ↑ "When is treatment indicated for high cholesterol level?". Archived from the original on 2012-07-30.
  66. ↑ "HIGHLIGHTS OF PRESCRIBING INFORMATION" (PDF). GlaxoSmithKline. September 2015. Archived (PDF) from the original on 2012-03-01. สืบค้นเมื่อ 2018-12-03.
  67. ↑ Wallace, JM; Schwarz, M; Coward, P; Houze, J; Sawyer, JK; Kelley, KL; Chai, A; Rudel, LL (2005). "Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys". J Lipid Res. 46: 1009–16. doi:10.1194/jlr.M500002-JLR200. PMID 15716581.CS1 maint: Multiple names: authors list (link)
  68. ↑ Hwang, JS; Ham, SA; Yoo, T; Lee, WJ; Paek, KS; Lee, CH; Seo, HG (2016). "Sirtuin 1 Mediates the Actions of Peroxisome Proliferator-Activated Receptor δ on the Oxidized Low-Density Lipoprotein-Triggered Migration and Proliferation of Vascular Smooth Muscle Cells". Mol Pharmacol. 90: 522–529. doi:10.1124/mol.116.104679. PMID 27573670.CS1 maint: Multiple names: authors list (link)

แหล่งที่มา

WikiPedia: ไลโพโปรตีนหนาแน่นสูง http://heartdisease.about.com/cs/cholesterol/a/rai... http://us.gsk.com/products/assets/us_lovaza.pdf http://cme.medscape.com/viewarticle/479499_5 http://cme.medscape.com/viewarticle/520393 http://www.webmd.com/vitamins-and-supplements/life... http://www.health.harvard.edu/newsletters/Harvard_... http://www.nhlbi.nih.gov/guidelines/cholesterol/at... //www.ncbi.nlm.nih.gov/pmc/articles/PMC1052533 //www.ncbi.nlm.nih.gov/pmc/articles/PMC1479303 //www.ncbi.nlm.nih.gov/pmc/articles/PMC1732002